Reports Q2 revenue $15.2M vs. $16.2M last year. Revenue was impacted by a deemphasis in marketing for the ADHD and pediatric portfolios as the company shifted focus to the launch of EXXUA. Reports ADHD portfolio net revenue $13.2M vs. $13.8M last year. “This is a truly momentous time for Aytu as we commercially launched EXXUA, the first and only 5HT1a agonist approved by the FDA for the treatment of MDD, representing a new way to treat MDD,” said CEO Josh Disbrow.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AYTU: